Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice |
| |
| Authors: | Romain Dacquin Nicolas Bonnet Marina Stolina Chun‐Ya Han Paul Kostenuik Pierre Jurdic Serge Ferrari Eleni Douni |
| |
| Institution: | 1. Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France;2. Department of Rehabilitation and Geriatrics, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland;3. Metabolic Disorders Research, Amgen Inc., Thousand Oaks, CA, USA;4. Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece;5. Biomedical Sciences Research Center “Alexander Fleming”, Vari, Greece |
| |
| Abstract: | Receptor activator of NF‐κB ligand (RANKL) plays a key role in osteoclast‐induced bone resorption across a range of degenerative bone diseases, and its specific inhibition has been recently approved as a treatment for women with postmenopausal osteoporosis at high or increased risk of fracture in the United States and globally. In the present study, we generated transgenic mice (TghuRANKL) carrying the human RANKL (huRANKL) genomic region and achieved a physiologically relevant pattern of RANKL overexpression in order to establish novel genetic models for assessing skeletal and extraskeletal pathologies associated with excessive RANKL and for testing clinical therapeutic candidates that inhibit human RANKL. TghuRANKL mice of both sexes developed early‐onset bone loss, and the levels of huRANKL expression were correlated with bone resorption and disease severity. Low copy Tg5516 mice expressing huRANKL at low levels displayed a mild osteoporotic phenotype as shown by trabecular bone loss and reduced biomechanical properties. Notably, overexpression of huRANKL, in the medium copy Tg5519 line, resulted in severe early‐onset osteoporosis characterized by lack of trabecular bone, destruction of the growth plate, increased osteoclastogenesis, bone marrow adiposity, increased bone remodeling, and severe cortical bone porosity accompanied by decreased bone strength. An even more severe skeletal phenotype developed in the high copy Tg5520 founder with extensive soft tissue calcification. Model validation was further established by evidence that denosumab, an antibody that inhibits human but not murine RANKL, fully corrected the hyper‐resorptive and osteoporotic phenotypes of Tg5519 mice. Furthermore, overexpression of huRANKL rescued osteopetrotic phenotypes of RANKL‐defective mice. These novel huRANKL transgenic models of osteoporosis represent an important advance for understanding the pathogenesis and treatment of high‐turnover bone diseases and other disease states caused by excessive RANKL. © 2014 American Society for Bone and Mineral Research. |
| |
| Keywords: | BONE OSTEOPOROSIS RANKL ANIMAL MODELS TREATMENT |
|
|
